Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Dow
Merck
McKinsey
McKesson

Last Updated: December 8, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,263,581


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,263,581 protect, and when does it expire?

Patent 8,263,581 protects QUZYTTIR and is included in one NDA.

This patent has five patent family members in five countries.

Summary for Patent: 8,263,581
Title:Non-sedating antihistamine injection formulations and methods of use thereof
Abstract: Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute allergic reactions including anaphylaxis with the compositions are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms. In other embodiments, the non-sedating or second and third generation antihistamine injectable formulations are therapeutically equivalent to diphenhydramine injectable formulations and/or are more effective than placebo. In other embodiments, a non-sedating antihistamine injectable composition is delivered by an autoinjector.
Inventor(s): Du; Jie (Lansdale, PA)
Assignee: JDP Therapeutics, Inc. (Lansdale, PA)
Application Number:12/704,089
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 8,263,581

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Jdp QUZYTTIR cetirizine hydrochloride SOLUTION;INTRAVENOUS 211415-001 Oct 4, 2019 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF ACUTE URTICARIA ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,263,581

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010266103 ⤷  Free Forever Trial
Canada 2803987 ⤷  Free Forever Trial
European Patent Office 2477634 ⤷  Free Forever Trial
Spain 2616703 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 2011003074 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
AstraZeneca
Dow
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.